Effective treatment with intravenous immunoglobulins reduces autoreactive T-cell response in patients with CIDP

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 86, Issue 6, 2015, Pages 686-691

  Klehmet, Juliane ^a   Goehler, Jos ^a   Ulm, Lena ^a   Kohler, Siegfried ^a   Meisel, Christian ^a   Meisel, Andreas ^a   Harms, Hendrik ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b St Josefs Krankenhaus Potsdam Sanssouci   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIGEN; GAMMA INTERFERON; IMMUNOGLOBULIN; MYELIN BASIC PROTEIN; PERIPHERAL MYELIN PROTEIN 22;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG EFFICACY; DRUG RESPONSE; EFFECTOR CELL; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNOLOGICAL MEMORY; IMMUNOMODULATION; IMMUNOREACTIVITY; INTERFERON PRODUCTION; MALE; MEMORY CELL; MONOCYTE; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; TREATMENT OUTCOME; IMMUNOLOGY; IMMUNOTHERAPY; MIDDLE AGED; MYELIN SHEATH; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; PROCEDURES; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; AUTOANTIGENS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; MALE; MIDDLE AGED; MONOCYTES; MYELIN SHEATH; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84929991494     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-307708     Document Type: Article

References (31)

1. Lunn MP, Manji H, Choudhary PP, et al. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999;66:677-80.
2. Hughes RA, Allen D, Makowska A, et al. Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. J Peripher Nerv Syst 2006;11:30-46.
3. Adam AM, Atkinson PF, Hall SM, et al. Chronic experimental allergic neuritis in Lewis rats. Neuropathol Appl Neurobiol 1989;15:249-64.
4. Van den Berg LH, Mollee I, Wokke JH, et al. Increased frequencies of HPRT mutant T lymphocytes in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy: further evidence for a role of T cells in the etiopathogenesis of peripheral demyelinating diseases. J Neuroimmunol 1995;58:37-42.
5. Yan WX, Archelos JJ, Hartung HP, et al. P0 protein is a target antigen in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 2001;50:286-92.
6. Csurhes PA, Sullivan AA, Green K, et al. T cell reactivity to P0, P2, PMP-22, and myelin basic protein in patients with Guillain-Barre syndrome and chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 2005;76:1431-9.
7. Sanvito L, Makowska A, Gregson N, et al. Circulating subsets and CD4 (+) CD25 (+) regulatory T cell function in chronic inflammatory demyelinating polyradiculoneuropathy. Autoimmunity 2009;42:667-77.
8. Zhu J, Link H, Mix E, et al. Th1-like cell responses to peripheral nerve myelin components over the course of experimental allergic neuritis in Lewis rats. Acta Neurol Scand 1994;90:19-25.
9. Sallusto F, Langenkamp A, Geginat J, et al. Functional subsets of memory T cells identified by CCR7 expression. Curr Top Microbiol Immunol 2000;251:167-71.
10. Abdulahad WH, van der Geld YM, Stegeman CA, et al. Persistent expansion of CD4+ effector memory T cells in Wegener's granulomatosis. Kidney Int 2006;70:938-47.
11. Sen Y, Chunsong H, Baojun H, et al. Aberration of CCR7 CD8 memory T cells from patients with systemic lupus erythematosus: an inducer of T helper type 2 bias of CD4 T cells. Immunology 2004;112:274-89.
12. Haegele KF, Stueckle CA, Malin JP, et al. Increase of CD8+ T-effector memory cells in peripheral blood of patients with relapsing-remitting multiple sclerosis compared to healthy controls. J Neuroimmunol 2007;183:168-74.
13. Hughes RA, Donofrio P, Bril V, et al. Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 2008;7:136-44.
14. Van Schaik IN, Winer JB, De Haan R, et al. Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 2002; (2): CD001797.
15. Kaneko Y, Nimmerjahn F, Ravetch JV. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 2006;313:670-3.
16. Stangel M, Pul R. Basic principles of intravenous immunoglobulin (IVIg) treatment. J Neurol 2006;253(Suppl 5):V18-24.
17. Anthony RM, Kobayashi T, Wermeling F, et al. Intravenous gammaglobulin suppresses inflammation through a novel T (H) 2 pathway. Nature 2011;475:110-13.
18. De Groot AS, Moise L, McMurry JA, et al. Activation of natural regulatory T cells by IgG Fc-derived peptide "Tregitopes". Blood 2008;112:3303-11.
19. Park-Min KH, Serbina NV, Yang W, et al. FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 2007;26:67-78.
20. Kessel A, Ammuri H, Peri R, et al. Intravenous immunoglobulin therapy affects T regulatory cells by increasing their suppressive function. J Immunol 2007;179:5571-5.
21. Cats E, van der Pol WL, Piepers S, et al. Correlates of outcome and response to IVIg in 88 patients with multifocal motor neuropathy. Neurology 2010;75:818-25.
22. Anthony DD, Lehmann PV. T-cell epitope mapping using the ELISPOT approach. Methods 2003;29:260-9.
23. Ott PA, Berner BR, Herzog BA, et al. CD28 costimulation enhances the sensitivity of the ELISPOT assay for detection of antigen-specific memory effector CD4 and CD8 cell populations in human diseases. J Immunol Methods 2004;285:223-35.
24. Currier JR, Kuta EG, Turk E, et al. A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 2002;260:157-72.
25. Dalakas MC. Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers. Curr Opin Neurol 1999;12:403-9.
26. Saperstein DS, Katz JS, Amato AA, et al. Clinical spectrum of chronic acquired demyelinating polyneuropathies. Muscle Nerve 2001;24:311-24.
27. Matteucci E, Ghimenti M, Di BS, et al. Altered proportions of naive, central memory and terminally differentiated central memory subsets among CD4+ and CD8+ T cells expressing CD26 in patients with type 1 diabetes. J Clin Immunol 2011;31:977-84.
28. Mikulkova Z, Praksova P, Stourac P, et al. Imbalance in T-cell and cytokine profiles in patients with relapsing-remitting multiple sclerosis. J Neurol Sci 2011;300:135-41.
29. Grubeck-Loebenstein B, Della Bella S, Iorio AM. Immunosenescence and vaccine failure in the elderly. Aging Clin Exp Res 2009;21:201-9.
30. Trebst C, Brunhorn K, Lindner M, et al. Expression of chemokine receptors on peripheral blood mononuclear cells of patients with immune-mediated neuropathies treated with intravenous immunoglobulins. Eur J Neurol 2006;13:1359-63.
31. Mausberg AK, Dorok M, Stettner M, et al. Recovery of the T-cell repertoire in CIDP by IV immunoglobulins. Neurology 2013;80:296-303.